Clinical Trial Update: A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease [Phase 2]

View source ↗

Summary

This update describes a long-term extension of a Phase 2 trial of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Diseases

Drugs mentioned

• RP103

Snippet

Sponsor: Amgen | Conditions: Mitochondrial Diseases | Phase 2 | Status: TERMINATED | Results posted: 2018-05-11